Lappuse 1 no 244 rezultātiem
OBJECTIVE
To examine the role of placental protein tyrosine nitration and p38-Mitogen-Activated Protein Kinase α (p38-MAPKα), Extra Cellular-Signal Regulated Kinase (ERK) and c-Jun NH2-Terminal Kinase (JNK) activity, in the pathogenesis of type 1 diabetic pre-eclampsia, and the putative modulation
OBJECTIVE
To investigate the expression of fms-like tyrosine kinase receptor 1 (Flt-1) in placentas of pre-eclampsia.
METHODS
The expression of Flt-1 mRNA in the placentas from 20 pre-eclampsia patients and 20 pregnant women with normal blood pressure was detected by semi-quantitative reverse
OBJECTIVE
To analyze a potential association of gene polymorphisms of the follicle-stimulating hormone receptor (FSHR) gene rs1394205 polymorphism and tyrosine hydroxylase (TH) rs2070762 polymorphism with pre-eclampsia.
METHODS
The gene polymorphism of FSHR rs1394205 and TH rs2070762 were analyzed
OBJECTIVE
We hypothesized that umbilical vein serum soluble fms-like tyrosine kinase 1 (sFlt1) concentration was augmented in pre-eclampsia. We also explored a possible association between fetal and maternal concentrations of sFlt1.
METHODS
At cesarean delivery, maternal serum samples from
To compare serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) concentrations among women with pre-eclampsia and healthy control women and to evaluate the associations of serum PlGF and sFlt-1 with fetal and uterine artery Doppler indices in BACKGROUND
We hypothesized that pre-eclampsia (PE) can be predicted early in primiparas by measuring serum levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF).
METHODS
All normotensive primiparas attending the antenatal clinics of Aga Khan University Hospital and
OBJECTIVE
To investigate the association between first trimester maternal placental growth factor (PlGF) and fms-like tyrosine kinase 1 (sFlt-1) levels with subsequent development of pre-eclampsia (PE).
METHODS
This is a matched case-control study using stored serum samples collected from
OBJECTIVE
To examine the distribution of maternal serum soluble fms-like tyrosine kinase-1 (sFlt-1) at 12, 22, 32 and 36 weeks' gestation in singleton pregnancies that develop pre-eclampsia (PE) and examine the performance of this biomarker in screening for PE.
METHODS
Serum sFlt-1 was measured in
OBJECTIVE
We studied the effect of pre-eclampsia sera on the expression of placenta growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), metal-responsive transcription factor-1 (MTF-1), heme oxygenase 1 (HO-1) and hypoxia inducible factor-1α (HIF-1α) mRNAs in JEG-3 cells
OBJECTIVE
To determine if pre-eclampsia is associated with reduced thyroid function during and after pregnancy.
METHODS
Nested case-control study during pregnancy and population based follow-up study after pregnancy.
METHODS
Calcium for Pre-eclampsia Prevention trial of healthy pregnant nulliparous
OBJECTIVE
To investigate longitudinal changes in maternal serum levels of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in pregnant women who develop pre-eclampsia (PE) or gestational hypertension (GH).
METHODS
This was a prospective longitudinal study in women with
Pre-eclampsia (PE) prediction based on blood pressure, presence of protein in the urine, symptoms and laboratory test abnormalities can result in false-positive diagnoses. This may lead to unnecessary antenatal admissions and preterm delivery. Blood tests that measure placental growth factor (PlGF)
OBJECTIVE
Short-term prediction of pre-eclampsia (PE) using the soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio is characterized by frequent false-positive results. As such, no treatment can be recommended to test-positive patients and multiple measurements are often
BACKGROUND
The precise origin of Pre-eclampsia (PE) remains elusive. Multiple pieces of evidence support the existence of hypoxia in PE. MiRNA-210 (miR-210), which is induced by Hypoxia-Inducible Factor-1α (HIF-1α) during hypoxia, is one of the most hypoxia sensitive miRNAs. MiR-210 mediates these
OBJECTIVE
To investigate the potential value of repeat measurements of maternal serum concentration of soluble fms-like tyrosine kinase-1 (sFlt-1) at 22 and 32 weeks' gestation in the prediction of pre-eclampsia (PE) in women delivering after 32 weeks.
METHODS
The data were derived from prospective